KSK. S. Semashchenko

K. S. Semashchenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


K. S. Semashchenko has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association of MIR146A (rs2910164) and MIR499A (rs3746444) gene polymorphisms with markers of thromboinflammation in patients with coronary heart disease after coronary artery bypass grafting

    by A. A. Kosinova, K. S. Semashchenko, T. N. Subbotina, Yu. I. Grinshtein, T. S. Mongush, D. Yu. Makarova, A. A. Shalyova

    Background . Advances in genomics and proteomics have facilitated the identification of numerous new candidate biomarkers for the diagnosis and prognosis of coronary heart disease (CHD), as well as for predicting adverse cardiovascular events, including post-coronary artery bypass grafting (CABG) outcomes. MicroRNAs represent a promising category of these biomarkers. Aim : To investigate the association between the rs2910164 polymorphism in the MIR146A gene and the rs3746444 polymorphism in the MIR499A gene with adverse cardiovascular events and general inflammation markers in CHD patients post-CABG. Material and Methods . This prospective cohort study involved 158 CHD patients with a median age of 63 years [58; 67]. Patients were assessed at three stages: preoperatively, on postoperative days 8–10, and post-discharge. Early in-hospital cardiovascular events were recorded over 8–10 days of hospitalization, and long-term events were tracked for an average of 36.1 ± 10.6 months post-CABG. Comprehensive blood analyses and leukocyte DNA genotyping were conducted preoperatively and on days 8–10 postsurgery. Additionally, flow cytometry and high-sensitivity C-reactive protein (CRP) measurement were performed on a random subset of 102 patients. Results . The allele frequencies of G and C (rs2910164) were 0.62 and 0.38, respectively, and those of A and G (rs3746444) were 0.83 and 0.17 in the CHD cohort. No significant differences in rare allele prevalence were observed between patients with and without long-term adverse cardiovascular events. Preoperatively, CHD patients with the GG genotype of rs2910164 MIR146A displayed higher plateletplatelet aggregate counts. Post-CABG, this genotype group showed significantly elevated values in platelet-platelet aggregate mean fluorescence intensity (MFI) (33.1 [31.5; 35.75] vs. 30.0 [29.0; 33.13], p = 0.001), MFI of P-selectin-expressing platelets (4.69 [2.05; 6.77] vs. 1.97 [1.49; 2.53], p = 0.002), MFI of P-selectin-expressing platelet–monocyte (6.71 [4.18; 16.4] vs. 4.22 [3.73; 6.14], p = 0.018), and MFI of P-selectin-expressing platelet-platelet aggregates (5.17 [2.47; 7.24] vs. 2.56 [1.7; 2.94], p = 0.003). The erythrocyte sedimentation rate (ESR) was significantly higher in patients with the C allele preoperatively (60.0 [31.0; 89.0] mm/hr vs. 40.0 [27.75; 57.75] mm/hr, p = 0.043). Conclusions . The presence of rare alleles in rs2910164 ( MIR146A ) and rs3746444 ( MIR499A ) was not associated with an increased frequency of in-hospital or long-term adverse cardiovascular events. However, CHD patients with the GG genotype of rs2910164 MIR146A post-CABG exhibited significantly higher MFI in platelet aggregates expressing P-selectin.

  • Open Access

    Postgenomic aspects of resistance to acetylsalicylic acid in patients with coronary artery disease

    by Yu. I. Grinshtein, A. A. Kosinova, A. N. Maltseva, T. N. Subbotina, K. S. Semashchenko, P. I. Levagina, E. O. Shavrina, A. A. Savchenko, Ю. И. Гринштейн

    Aim. To study the expression level of the P-selectin gene (SELP) mRNA and the level of intercellular interaction in patients with coronary artery disease (CAD) before and after coronary artery bypass grafting (CABG) in patients with resistance to acetylsalicylic acid (ASA).Material and methods. The study included 65 patients with CAD who were scheduled to CABG. SELP expression, the platelet-leucocyte aggregate level, and the level of P-selectin expression on aggregates were determined in all participants. Resistance to ASA was defined as platelet aggregation with arachidonic acid ≥20% in at least one sample. All studies were performed before and on the 8th-10th day after CABG.Results. Among patients, 29,4% (n=30) were resistant to ASA (ASA-R) at least at one point, while 7,8% (n=8) acquired resistance after CABG. ASA-R had a higher level of SELP (0,41 [0,28; 0,48] vs 0,32 [0,23; 0,39], p=0,037), absolute content of monocyte-platelet aggregates (24,70 [9,69; 39,90] vs 10,15 [5,27; 30,63], p=0,037) and relative amount of platelet-platelet CD62P aggregates (7,37% [3,43; 35,49] vs 4,84% [0,90; 9,63], p=0,045). A negative correlation was found between SELP expression and the relative content of monocyte-platelet aggregates (ρ=-0,349, p=0,013) on days 8-10 after CABG. Mmultivariate regression analysis found that the level of SELP gene mRNA expression is a predictor of ASA resistance before CABG (odds ratio 404,48; 95% confidence interval 1,68-97461,63).Conclusion. Increased SELP expression is associated with an increase in platelet aggregation activity, which contributes to an insufficient platelet response to antithrombotic therapy in patients with CABG. The level of SELP gene mRNA expression can be considered as a predictor of ASA resistance.


  • Open Access

    Analysis of somatic mutations in the JAK2, CALR, MPL and ASXL1 genes and evaluation of their impact on the survival of patients with myelofibrosis

    by T. N. Subbotina, I. E. Maslyukova, K. S. Semashchenko, G. A. Khodos, D. V. Kurochkin, A. A. Shalyova, M. A. Mikhalev, E. V. Vasiliev, M. G. Osadchaya, E. A. Dunaeva, et al.

    Background. The development of myelofibrosis (MF) is driven by complex molecular genetic events that include driver somatic mutations responsible for the constitutive activation of the JAK/STAT signaling pathway (JAK2, CALR, and MPL), additional mutations affecting epigenetic regulators (TET2, ASXL1, IDH1/2, etc.) and RNA splicing (SRSF2, U2AF1, SF3B1, etc.), as well as genetic aberrations that contribute to genomic instability and disease progression.Aim. To analyze driver (JAK2, CALR, MPL) and prognostic (ASXL1) somatic mutations in patients with MF and evaluate their impact on survival.Materials and methods. The study included 29 patients diagnosed with MF, selected by hematologists from the City Clinical Hospital No. 7 and Regional Clinical Hospital (Krasnoyarsk).Results. 26 (89.6 %) out of 29 examined patients had some driver mutations in JAK2, CALR, MPL genes. The p.V617F mutation in the JAK2 gene was found in 20 (68.9 %) patients. Mutations in the CALR gene were detected in 4 (13.8 %) patients, mutations in the MPL gene were found in 3 patients (10.3 %). In 1 of 26 patients, 2 driver mutations were present simultaneously. 3 (10.3 %) patients were triple negative. Mutations in the ASXL1 gene were detected in 12 (41.4 %) out of 29 examined patients. Conducted targeted NGS (next generation sequencing) for 13 out of 29 patients revealed additional genetic variants that contribute to the understanding of the development mechanism and disease course. When evaluating the overall survival in the groups of patients diagnosed with MF examined by us, depending on the combination of driver (JAK2, CALR, MPL) and prognostic (ASXL1) mutations, no statistically significant differences were found (p = 0.12). This appears to be due to the small sample size. At the same time, assessment of patient survival depending on ASXL1 status showed that in the presence of mutations in the ASXL1 gene, the median survival was 45 months (range 7–120 months), while in the absence of mutations it was 48 months (range 21–359 months) (p = 0.03).Conclusion. The results obtained allow us to assume that the presence of mutations in the ASXL1 gene is an unfavorable factor in the course of the disease.


  • Open Access

    Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease

    by K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein

    Aim. To study the association of nucleotide polymorphisms in platelet receptor and cytochrome P450 genes with the development of resistance to antiplatelet drugs in CHD patients.Material and Methods. The study included 243 patients diagnosed with CHD after coronary artery bypass surgery (CABG), including 140 patients in the acetylsalicylic acid (ASA) treatment group and 103 patients in the dual antiplatelet therapy (DAT) group. All patients were tested for platelet aggregation using an optical aggregometer with inducers: 5 mM ADP and 1 mM arachidonic acid (AA). DNA samples were analyzed by allele-specific PCR for the presence of polymorphisms rs2046934, rs1126643, rs5918, rs6065, rs4244285 in the platelet receptor and cytochrome P450 genes.Results. No statistically significant differences were found during comparison of the prevalence of the studied polymorphisms in the platelet receptor and cytochrome P450 genes between the groups of aspirin-sensitive and aspirin-resistant patients, as well as between the groups of clopidogrelsensitive and clopidogrel-resistant patients. No association between carriage of the minor and major alleles of the polymorphisms studied and the development of antiplatelet drug resistance was found. In the group of patients on ASA therapy, carriers of the C allele of the T1565C (rs5918) ITGB3 polymorphism had a higher rate of AA-induced platelet aggregation compared to carriers of the T allele (18,49±25,92 vs 10,43±17,34, р=0,004).Conclusion. Polymorphisms of P2RY12 (rs2046934), ITGA2 (rs1126643), ITGB3 (rs5918), GP1BA (rs6065), CYP2C19*2 (rs4244285) genes are not associated with antiplatelet drug resistance in both patients on ASC therapy and on DAT. The presence of minor alleles of the rs2046934, rs1126643, rs6065, rs4244285 polymorphisms are not associated with increased platelet aggregation activity before CABG.However, in the group of patients on ASA therapy C-allele carriers of the rs5918 polymorphism of the ITGB3 gene had a higher rate of AA-induced platelet aggregation compared to T-allele carriers.


  • Study of serum procalcitonin and lactate levels in women with preeclampsia

    by Semashchenko K.S Semashchenko, Vasilyeva E.V. Vasilyeva, Molokova N.N. Molokova, Zhitkova O. Yu. Zhitkova O, Subbotina T.N. Subbotina, Krasnoyarsk City Maternity Hospital No. 5

  • Open Access

    Association of T715P (RS6136), M62I (RS2228315), S290N (RS6131), V640L (RS6133) polymorphisms in the P-selectin gene and its ligand with acetylsalicylic acid resistance in patients with coronary artery disease after coronary artery bypass grafting

    by A. A. Kosinova, T. S. Mongush, M. D. Goncharov, T. N. Subbotina, K. S. Semashchenko, G. Yu. Kochmareva, Yu. I. Grinshtein, Ю. И. Гринштейн

    Aim.To study the association of T715P (rs6136), M62I (rs2228315), S290N (rs6131), V640L (rs6133) polymorphisms in the P-selectin gene with resistance to acetylsalicylic acid (ASA) in patients with coronary artery disease after coronary artery bypass grafting (CABG).Material and methods. The study included 90 patients aged 61,5±6,9 years (70 men and 20 women) with II-IV functional class (FC) angina pectoris, according to the Canadian Cardiovascular Society grading. The atherosclerotic nature of coronary artery disease is confirmed by coronary angiography. Patients stopped taking antiplatelet agents before CABG for at least 5 days. The aggregation study was carried out with an optical aggregometer using ADP inducers (5 pM) and arachidonic acid (1 µМ) before CABG, on 1-3 and 8-10 days after surgical treatment.DNA samples were examined for the presence of T715P (rs6136), M62I (rs2228315), S290N (rs6131), V640L (rs6133) polymorphisms in the P-selectin gene using realtime PCR with allele-specific primers.Results.When comparing aPTT, fibrinogen level, platelet aggregation activity with ADP inducers (5 µМ) and arachidonic acid (1 µМ), no differences were found among groups of patients with homozygous and heterozygous variants of the studied polymorphisms genotypes, both before and on 1-3, 8 -10 days after CABG. Regarding presence of ASA resistance, patient groups with homozygous variants of genotypes (T715P (rs6136), M62I (rs2228315), S290N (rs6131), V640L (rs6133)) did not statistically differ in prevailing or rare alleles from the corresponding groups with heterozygous genotypes. In the first 10 days of the postoperative period, thrombotic events (4,4%) were observed in 4 patients in the study group: acute myocardial infarction, acute cerebrovascular accident. Regarding frequency of adverse events in the first 10 days after CABG, between groups of patients with homozygous variants of the studied genotypes (T715P (rs6136), M62I (rs2228315), S290N (rs6131), V640L (rs6133) in prevailing allele and groups with heterozygous variants of the corresponding genotypes there were also no statistically significant differences.Conclusion.Rs6133, rs6163, rs2228315, rs6131 polymorphisms in the platelet P-selectin gene are not associated with ASA resistance and are not associated with increased platelet aggregation activity in patients with coronary artery disease. The rare T, C, G, A alleles of the studied polymorphisms do not lead to an increase in the risks of adverse events in the first 10 days after CABG.